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Abstract
Upper gastrointestinal bleeding is a major adverse event of non-steroidal anti-inflammatory
drugs (NSAIDs), and co-administration of proton pump inhibitors and H2 receptor antagonists has
been established as a means of preventing such an eff ect. However, the incidence of bleeding as-
sociated with NSAID-induced ulcers under conditions where such strong anti-acid agents are used
for prevention has yet to be clarified. We aimed to determine the annual incidence of serious upper
gastrointestinal ulcer bleeding among Japanese patients in whom NSAIDs were used in our hospi-
tal. Before commencing the study, we recommended to all the physicians in our hospital the best
method for caring for NSAID users, focusing on the concomitant use of proton pump inhibitors
or H2 receptor antagonists. We conducted a cohort study involving 17,270 patients for whom
NSAIDs had been newly prescribed. Bleeding from gastric ulcers was observed in 8 of the 17,270
patients using NSAIDs (0.05%). The pooled incidence rate for bleeding was calculated as 2.65
(95% confidence interval, 2.56-2.74) and 1.29 (1.27-1.31) per 1,000 patient years for low-dose
aspirin and non-aspirin NSAID users, respectively. None of the bleeding ulcer patients required
blood transfusion or were in serious condition. In conclusion, gastric ulcer bleeding occurred in
low-dose aspirin or non-aspirin NSAID users, but its incidence was low and outcomes were not
serious when adequate preventive measures were taken.
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on-steroidal anti-inﬂ ammatory drugs (NSAIDs),  
including low-dose aspirin, are widely used.  
Their use can,  however,  cause gastrointestinal injury,  
and especially gastric or duodenal ulcers.  In Western 
countries,  many deaths due to hemorrhage and perfo-
ration from NSAID-induced ulcers have been reported 
[1,  2].  Several methods have been recommended to 
help prevent serious gastrointestinal complications,  
i.e.,  use of cyclooxygenase (COX)-2 inhibitors [3,  4] 
and/or concomitant proton pump inhibitors (PPIs) [5,  
6],  high-dose H2 receptor antagonists (H2RAs) [7],  
or prostaglandins [8],  especially in high-risk patients 
N
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such as those with a history of peptic ulcer disease.  
Unfortunately,  the use of COX-2 inhibitors was not 
authorized in Japan until June 2007.  The use of pros-
taglandins is limited by the occurrence of gastrointes-
tinal adverse eﬀ ects,  particularly diarrhea [9],  and 
marketing authorization has not been granted for the 
use of high-dose H2RAs in Japan.  Accordingly,  we 
took the following steps to prevent serious gastroin-
testinal complication in our patients using NSAIDs.  
Arranged as a private meeting,  2 gastroenterologists,  
a cardiologist,  an orthopedist,  and 2 pharmacists met 
to discuss the risk of NSAID-induced ulcers and the 
adequate management of patients.  From that meeting,  
they emphasized prevention using anti-ulcer agents and 
on December 2002 recommended concomitant use of 
PPIs for the prevention of NSAID-induced bleeding 
ulcers to all physicians working within our hospital 
(Table 1).  However,  the eﬃ  cacy of such methods for 
preventing NSAID-induced gastroduodenal ulcers and 
bleeding from these lesions has yet to be clariﬁ ed in 
Japan.  In the present study,  we aimed to determine 
the annual incidence of serious upper gastrointestinal 
bleeding among Japanese patients being treated with 
NSAIDs in our hospital,  where steps had been under-
taken to prevent serious complications of NSAID use.
Materials and Methods
　 Following the recommendation to manage NSAID 
users with concomitant PPIs,  the Division for Medical 
Informatics at our hospital collected monthly data on 
patients given NSAIDs,  and medical records included 
prior history of ulceration,  endoscopic examination 
and hospitalization.  Between January 2003 and 
December 2004,  18,048 patients (8,588 male and 
9,460 female,  mean age 51.5±20.7 years) received 
NSAIDs in our hospital.  Indications for NSAIDs 
included cardiovascular disease,  cerebrovascular dis-
ease,  arthritis,  fever,  and pain control.
　 Endoscopic examinations were performed for 
patients with hematemesis and/or tarry stools,  as 
conﬁ rmed by hospital staﬀ ,  for anemia from a blood 
examination.  Bleeding ulcers were deﬁ ned in accor-
dance with Forrest’s classiﬁ cation [10].  NSAID-
induced ulcer was deﬁ ned by the use of NSAID at the 
time of onset of ulcer bleeding,  regardless of the 
duration of NSAID use.  For patients with NSAID-
induced ulcer bleeding,  we investigated their charac-
teristics and background,  concomitant drug use 
including anticoagulants other than NSAIDs,  and 
duration from the start of NSAID use to the time of 
bleeding.  Helicobacter pylori (H.  pylori) infection was 
assessed in these patients by the measurement of 
serum immunoglobulin G antibodies (Determiner H.  
pylori antibody J; Enteric products,  Kyowa Medix,  
Tokyo,  Japan [11],  and E plate Eiken H.  pylori 
antibody; Eiken Chemical,  Tokyo,  Japan [12]).  The 
sites of bleeding ulcers were divided into the upper,  
middle,  and lower stomach as well as the duodenum.  
For multiple ulcers occurring across several sites,  the 
major bleeding lesion was selected.  Re-bleeding was 
determined as recurrent bleeding after initial stabili-
zation.  The endpoint of this study was serious ulcer 
bleeding in need of urgent endoscopic examination 
using a hemostatic procedure such as clipping of the 
exposed vessel on the ulcer.
　 Statistical analysis. The incidence of bleeding 
associated with NSAID-induced ulcers was calculated 
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Table 1　　Recommendation for the management of NSAID users in our hospital,  submitted on December 2002
On prescription of low dose aspirin
First,  ask the patient about their history of previous peptic ulcer disease.
If yes,  use concomitant use PPIs＊.
Even if no,  use concomitant use PPIs＊ or H2RAs in patients with serious underlying disease such as ischemic heart disease,  arrhythmia 
with cardiac valve disease,  or cerebral infarction.
On prescription of other NSAIDs
First,  ask the patient about their history of previous peptic ulcer disease.
If yes,  use concomitant use PPIs＊.
Discuss the possibility of adverse events associated with NSAID use,  especially gastrointestinal injury,  and if necessary,  do not 
hesitate to consult with a gastroenterologist.
＊Half-dose PPI is available.
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in terms of patient years with a 95ｵ conﬁ dence inter-
val.
Results
　 A ﬁ nal assessment was conducted in June 2005.  
Patients were divided into the following 2 groups:
patients taking low-dose aspirin,  and those taking non-
aspirin NSAIDs.  We categorized the patients who 
continuously used low-dose aspirin and occasionally 
used non-aspirin NSAIDs as being in the low-dose 
aspirin group.  A ﬂ ow diagram in Fig.  1 shows the 
details of low-dose aspirin users and non-aspirin 
NSAIDs users focusing on concomitantly used anti-
ulcer agents.  Six hundred twenty-nine patients were 
lost to follow-up,  148 died of other diseases: 67 of 
their original malignant disease,  23 of cardiovascular 
disease,  21 of cerebrovascular disease,  17 of pneu-
monia,  10 of liver failure,  7 of renal failure,  and 3 in 
traﬃ  c accidents,  while 1 patient underwent H.  pylori 
eradication therapy 2 days after administration of 
loxoprofen.  We therefore analyzed 17,270 patients 
(8,105 male and 9,165 female,  mean age 50.8±20.7 
years).  Of these 17,270 patients,  8,815 periodically 
came for hospital visits,  7,613 returned to our hospi-
tal for follow-up after their last NSAID prescription,  
and 992 were interviewed by telephone.  In the 17,270 
NSAID users,  1,657 (9.6ｵ) were taking low-dose 
aspirin and 15,613 were taking non-aspirin NSAIDs 
(90.4ｵ).  The NSAIDs used in this study were low-
31Incidence of Bleeding NSAID UlcersFebruary 2008
18,048 patients enrolled
1,734 patients on low-dose aspirin 16,314 patients on non-aspirin NSAID
77 patients excluded
62 lost to followed-up
15 died from other disease
700 patients excluded
567 lost to followed-up
133 died from other disease
One received H. pylori eradication
1,657 patients on low-dose aspirin assessed 15,613 patients on non-aspirin NSAID assessed
Concomitant drugs
PPI PPIH2RA H2RACA CAPG PGNone None
178 (24＊) 1,064 (104＊) 1,449 (96＊) 5,414 (4＊) 35 (1＊) 7,651 (19＊)431 (49＊) 229 (7＊) 0 (0＊) 819 (18＊)
0 0 02 0 0 021
(0.0%) (0.0%) (0.12%) (0.0%) (0.0%) (0.0%)(0.013%) (0.019%)(0.0%) (0.06%)
3
Bleeding ulcer
Fig. 1　　Flow diagram of patients.  
Asterisks represent the number of patients with a history of peptic ulcers.
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dose aspirin (80ﾝ325 mg; Buﬀ erin 81 mg and 
Bayaspirin,  a 100 mg enteric-coated tablet) and other 
NSAIDs (loxoprofen,  diclofenac sodium,  aminosali-
cylic acid,  zaltoprofen,  serrapeptase,  indomethacin,  
etodolac,  tiaramide,  or mefenamic acid) (Table 2).  
Loxoprofen was the most frequently used NSAID 
(44.2ｵ).
　 Concomitantly used anti-ulcer agents included 
PPIs (lansoprazole 15 or 30 mg,  omeprazole 20 mg,  
or rabeprazole 10 or 20 mg),  H2RAs (famotidine 
20 mg,  ranitidine 150 mg or cimetidine 200 mg),  
prostaglandin (misoprostol),  or cytoprotective anti-
ulcer agents (ecabet sodium,  sucralfate,  teprenone,  
sodium alginate,  polaprezinc,  cetraxate,  rebamipide,  
or sulfonic acid).  The proportion of PPIs used in this 
study is shown in Fig.  2,  and ordinary-dose lansopra-
zole (30 mg) or half-dose lansoprazole (15 mg) were 
the most frequently used PPIs with NSAIDs (32.5ｵ 
and 30.2ｵ,  respectively).
　 Of the 1,657 patients on low-dose aspirin,  178 
(10.7ｵ) were given a PPI concomitantly,  431 (26.0
ｵ) were given an H2RA,  229 (13.8ｵ) were given a 
cytoprotective anti-ulcer agent,  and 819 (49.4ｵ) were 
not given anti-ulcer agents.  Of the 15,613 patients on 
non-aspirin NSAIDs,  1,064 (6.8ｵ) were given a PPI 
concomitantly,  1,449 (9.3ｵ) were given an H2RA,  
5,414 (24.7ｵ) were given a cytoprotective anti-ulcer 
agent,  and 35 (0.2ｵ) were given prostaglandin,  while 
7,651 (48.8ｵ) patients were not given any anti-ulcer 
agents (Fig.  1).  Of the 17,270 NSAID users,  322 
(1.9ｵ) had a history of peptic ulcer (98 on low-dose 
aspirin and 224 on non-aspirin NSAIDs),  and 128 of 
these patients were given a PPI (39.8ｵ),  145 were 
given an H2RA (45.0ｵ),  and the remaining 49 were 
given other anti-ulcer agents or nothing at all 
(15.2ｵ).
　 Bleeding gastric ulcers developed in 8 of the 
17,270 NSAID users (0.05ｵ),  but none of the 8 had 
a history of a peptic ulcer or of anti-coagulant therapy 
other than low-dose aspirin.  In the 1,657 low-dose 
aspirin users,  when stratiﬁ ed by concomitant anti-
ulcer agents,  the proportion who developed bleeding 
ulcers was as follows: none in the PPI or H2RA 
groups,  0.12ｵ in the cytoprotective anti-ulcer agent 
group,  none in the prostaglandin group,  and 0.06ｵ in 
the no anti-ulcer agent group.  In the 15,613 non-
aspirin NSAID patients,  the proportion who devel-
oped bleeding ulcers was as follows: none in the PPI 
group,  0.013ｵ in the H2RA group,  none in the cyto-
protective anti-ulcer agent or prostaglandin groups,  
and 0.019ｵ in the no anti-ulcer agent group.  No 
bleeding ulcers developed in the NSAID users given 
concomitant PPIs (Fig.  1).
　 Table 3 shows the characteristics of NSAID users 
in whom bleeding ulcers developed,  and the incidence 
rate of bleeding ulcers.  The 8 patients with bleeding 
ulcers comprised 3 low-dose aspirin users (2 with 
cytoprotective agents and 1 without an anti-ulcer 
agent) and 5 non-aspirin NSAID users (2 with H2RAs 
and 3 without an anti-ulcer agent).  Four of the 8 
bleeding ulcers (50.0ｵ) were located in the middle of 
the stomach,  and 3 (37.5ｵ) were located in the lower 
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Table 2　　Details of NSAIDs used in this study
Drug Casenumber (%)
Loxoprofen 7,640 (44.2%)
Diclofenac Na 3,187 (18.5%)
Low dose aspirin 1,657 ( 9.6%)
Aminosalicylic acid 1,609 ( 9.3%)
Zaltoprofen 908 ( 5.3%)
Serrapeptase 716 ( 4.1%)
Indomethacin 568 ( 3.3%)
Etodolac 563 ( 3.3%)
Tiaramide 259 ( 1.5%)
Mefenamic acid 127 ( 0.7%)
Other 36 ( 0.2%)
Total 17,270 (100%)
Rabeprazole 10 mg
(2.6%)
Rabeprazole 20 mg
(22.5%)
Lansoprazole 15 mg
(30.2%)
Lansoprazole 30 mg
(32.5%)Omeprazole 20 mg
(12.2%)
Fig. 2　　Details of concomitant PPIs used in this study.
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region.  We conducted endoscopic hemostasis for all 
patients,  and none of the bleeding ulcer patients 
required blood transfusion or were in serious condi-
tion.  Serum anti-H.  pylori antibody was detected in 5 
of the 8 (62.5ｵ) patients with bleeding ulcers.  One 
patient was a low-dose aspirin user,  and 4 were non-
aspirin NSAID users (Table 3).
　 As shown in Table 3,  the incidence rates for 
bleeding per 1,000 patient years (95ｵ conﬁ dence 
interval) for all NSAID users,  low-dose aspirin users,  
and non-aspirin NSAID users were 1.60 (1.58ﾝ1.61),  
2.65 (2.56ﾝ2.74),  and 1.29 (1.27ﾝ1.31),  respectively.  
For the patients taking low-dose aspirin,  the incidence 
rate stratiﬁ ed by concomitantly used anti-ulcer agents 
was as follows: 0 for the PPI and H2RA groups,  
1.72 (1.58ﾝ1.86) for the no anti-ulcer agent group,  and 
14.4 (12.7ﾝ16.1) for the cytoprotective anti-ulcer 
agent group.  Because none of the patients taking low-
dose aspirin received prostaglandin,  we could not 
calculate the incidence rate.  In patients using non-
aspirin NSAIDs,  the incidence rate was as follows: 0 
for the PPI,  cytoprotective anti-ulcer agent and pros-
taglandin groups; 1.57 (1.53ﾝ1.61) for the no anti-
ulcer agent group; and 5.54 (5.13ﾝ5.94) for the H2RA 
group.
Discussion
　 To prevent serious adverse events associated with 
NSAID use,  i.e., gastrointestinal bleeding,  in 
December 2002,  we recommended to all physicians in 
our hospital that they manage NSAID users with con-
comitant PPIs or H2RAs.  In the present study,  we 
determined the annual incidence of serious upper gas-
trointestinal bleeding in 17,270 patients taking newly 
prescribed NSAIDs in our hospital,  after the time of 
the above recommendation.  We found that upper gas-
trointestinal ulcer bleeding occurred in low-dose aspi-
rin or non-aspirin NSAID users,  but its incidence was 
low and outcomes did not become serious when ade-
33Incidence of Bleeding NSAID UlcersFebruary 2008
Table 3　　Characteristics of patients who developed a bleeding ulcer
Concomitant anti-ulcer agent
Low dose aspirin Non-aspirin NSAID
Total
none PPI H2RA CA PG total none PPI H2RA CA PG total
No.  of patients 1 0 0 2 0 3 3 0 2 0 0 5 8
Sex (male/female) 1/0 0 0 1/1 0 2/1 2/1 0 1/1 0 0 3/2 5/3
Age 61 0 0 55, 86 0 61
(55ﾝ86)＊
62, 76, 81 0 38, 77 0 0 76
(38ﾝ81)＊
69
 (38ﾝ86)＊
HP infection 0 0 0 1 0 1 3 0 1 0 0 4 5
Underlying disease
Cardiovascular disease 1 0 0 1 0 2 0 0 0 0 0 0 2
Cerebrovascular disease 0 0 0 1 0 1 0 0 1 0 0 1 2
Arthritis 0 0 0 0 0 0 2 0 1 0 0 3 3
Others 0 0 0 0 0 0 1 0 0 0 0 1 1
Time until bleeding (day) 480 0 0 63, 94 0 94
(63ﾝ480)＊
4, 28, 144 0 15, 39 0 0 28
(4ﾝ144)＊
51
(4ﾝ480)＊
Site of bleeding ulcer
Upper stomach 1 0 0 0 0 1 0 0 0 0 0 0 1
Middle stomach 0 0 0 2 0 2 1 0 1 0 0 2 4
Lower stomach 0 0 0 0 0 0 2 0 1 0 0 3 3
Duodenum 0 0 0 0 0 0 0 0 0 0 0 0 0
Forrest’s classiﬁ cation Ib Ib, IIa Ia, Ib, IIa IIa, IIa
Patient-year of exposure 580.5 107.5 305.5 139 0 1,132.5 1,915.25 267.5 361.25 1,329 7.75 3,880.75 5,013.75
Bleeding events 1 0 0 2 0 3 3 0 2 0 0 5 8
Incidence rate per 1,000 
patients/year
1.72 0 0 14.4 NC 2.65 1.57 0 5.54 0 0 1.29 1.60
(95% Conﬁ dence Interval) 1.58ﾝ1.86 0 0 12.7ﾝ16.1 NC 2.56ﾝ2.74 1.53ﾝ1.61 0 5.13ﾝ5.94 0 0 1.27ﾝ1.31 1.58ﾝ1.61
CA,  cytoprotective anti-ulcer agent; NC,  not calculated; PG,  prostaglandin.
＊median (range).
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quate measures were taken to prevent bleeding.
　 The association between NSAID use and the devel-
opment of peptic ulcers may involve several mecha-
nisms.  Aspirin acts locally in the stomach through the 
release of salicylic acid,  which directly injures the 
gastric epithelial cells and promotes topical inﬂ amma-
tion by inducing the recruitment of leukocytes [13].  
The systemic gastrotoxic eﬀ ects of aspirin are related 
to the inhibition of COX-1,  which disrupts prostaglan-
din production,  as seen with other NSAIDs [3,  13].  
Because aspirin possesses an anti-platelet function 
that promotes bleeding complications,  in this study we 
analyzed low-dose aspirin separately from other 
NSAIDs.
　 Of the 17,270 patients using low-dose aspirin and 
non-aspirin NSAIDs,  gastric ulcer bleeding was 
observed in 8 patients (0.05ｵ).  The pooled incidence 
rates in low-dose aspirin and non-aspirin NSAID users 
for bleeding per 1,000 patient years were calculated 
as 2.65 (95ｵ conﬁ dence interval: 2.56ﾝ2.74) and 
1.29 (1.27ﾝ1.31),  respectively.  The 2 largest random-
ized clinical trials [14 ,15] on low-dose aspirin 
reported an incidence of upper gastrointestinal bleed-
ing of 7 per 1,000 patient-years and 3 per 1,000 
patient-years respectively.  On the other hand,  
Serrano et al.  [16] have reported an incidence of 12 
per 1,000 patient-years associated with low-dose aspi-
rin use in patients suﬀ ering from cardiovascular dis-
ease in a clinical setting,  a higher rate than reported 
previously.  In randomized clinical trials,  patients with 
risk factors for gastrointestinal bleeding (e.g.  ulcer 
history) are excluded; the incidence rate of 2.65 per 
1,000 patient years in our study is similar to that of 
the randomized trials.
　 Although many studies have shown that there is a 
risk of NSAID-associated bleeding peptic ulcers [17,  
18],  there is very little information available regard-
ing the incidence of non-aspirin NSAID-induced upper 
gastrointestinal bleeding.  Taha et al.  [19] have 
recently reported,  using 2,002 data from Scotland 
where PPI or H2RA are commonly prescribed with 
NSAIDs,  and where one-third of the non-aspirin 
NSAID users were also taking COX-2 selective inhib-
itors,  that the incidences of upper gastrointestinal 
bleeding in low-dose aspirin and non-aspirin NSAID 
users were 0.266 and 0.133 per 1,000 patient years,  
respectively.  These ﬁ gures are approximately one-
tenth lower than ours.
　 A diﬀ erence between our study and that of Taha et 
al.  [19] is that COX-2 selective inhibitors,  which 
have been proven to have a better gastrointestinal 
safety proﬁ le than traditional non-selective NSAIDs,  
were not granted marketing authorization in Japan 
until June 2007.  Thus,  the NSAIDs used in our study 
were non-selective NSAIDs.  The use of COX-2 selec-
tive inhibitors may reduce the incidence of upper gas-
trointestinal bleeding in Japan.  However,  despite the 
general decline in gastrointestinal adverse events,  
there is evidence to suggest that there is an increased 
relative risk for cardiovascular events associated with 
COX-2 selective inhibitors [20],  and rofecoxib has 
been withdrawn from the market as a result.  Thus,  
the trend is currently in favor of a non-selective 
NSAID plus a gastroprotective agent [21] such as 
PPIs and prostaglandins.  We have recommended the 
concomitant use of PPIs in our hospital,  especially 
for patients with a history of peptic ulcer.  Indeed,  
ulcer bleeding was not observed in patients who were 
taking concomitant PPIs either with low-dose aspirin 
or non-aspirin NSAIDs.  In contrast,  ulcer bleeding 
developed in 2 of 1,449 patients who were taking non-
aspirin NSAID with concomitant H2RAs.  There is 
some concern regarding the interaction between war-
farin and PPIs,  both of which are metabolized by 
cytochrome P450 2C19 in the liver [22].  Therefore,  
we allowed the use of H2RAs,  which is supported by 
a recent report in Japan that normal-dose H2RAs may 
be eﬀ ective in the prevention of low-dose aspirin-
induced ulcers because of low gastric acidity [23].  
Indeed,  H2RAs were eﬀ ective in preventing ulcer 
bleeding in patients taking low-dose aspirin,  but they 
were not suﬃ  ciently eﬀ ective for non-aspirin NSAID 
users.  Our ﬁ ndings support the use of PPIs or pros-
taglandins in non-aspirin NSAID users.
　 Another probable explanation for the higher inci-
dence of ulcer bleeding in our study is the high preva-
lence of H.  pylori infection in Japan,  especially in 
older people; more than 80ｵ of people over 50 years 
of age are infected with the bacterium.  H.  pylori 
infection [24] is another important cause of peptic 
ulcer,  and it acts synergistically with NSAIDs to 
induce peptic ulcer development and bleeding.  The 
risk of ulcer bleeding has been shown to be increased 
1.8-fold by H.  pylori infection,  4.85-fold by NSAID 
use,  and 6.1-fold by the presence of both factors,  
compared to the risk of bleeding among H.  pylori-neg-
34 Acta Med.  Okayama　Vol.  62,  No.  1Ishikawa et al.
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ative subjects not taking NSAIDs [24].  Conﬂ icting 
results have been reported regarding the eﬀ ects of H.  
pylori eradication therapy on the prevention of upper 
gastrointestinal adverse events in NSAID users [25,  
26].  Further studies are needed to clarify the preven-
tative eﬀ ects of eradication therapy on gastric ulcer 
bleeding in our NSAID patients.  However,  given the 
fact that H.  pylori eradication may reduce the risk of 
gastric cancer [27,  28],  as well as prevent recur-
rence of peptic ulcers and their bleeding,  it should be 
considered as an appropriate means of preventing 
upper gastrointestinal adverse events in patients 
treated with NSAID and selective COX-2 inhibitors 
with concomitant administration of PPIs,  especially in 
those with a high prevalence of H.  pylori infection.
　 In Japanese patients with a previous history of 
peptic ulcer disease,  a trial will soon be underway 
that will examine whether PPIs can suppress the 
development of NSAID-induced ulcers.  The endpoint 
for our investigation was NSAID-induced ulcer bleed-
ing.  The results of our study suggest that inhibitory 
eﬀ ects of PPIs on the development of NSAID-induced 
ulcers will likely be demonstrated in the aforemen-
tioned trial.  However,  our study also indicates the 
need for a more eﬀ ective treatment strategy in the 
eradication of NSAID-induced peptic ulcer bleeding.  
In Japan,  the clinical use of COX-2 selective inhibi-
tors has now become possible for the prevention of 
NSAID-induced ulcers.  However,  in Japan,  investi-
gations regarding the eﬃ  cacy and toxicity proﬁ le such 
as cardiovascular events of COX-2 selective inhibitors 
have not yet been fully realized.  Therefore,  further 
study is necessary regarding the prophylaxis of 
NSAID-induced ulcers in a Japanese population.
　 In summary,  the objective of our study was not to 
compare preventive eﬀ ects against NSAID-induced 
ulcer bleeding of the drugs concurrently administered 
with NSAIDs.  Rather,  our study purpose was to elu-
cidate the incidence of NSAID-induced ulcer bleeding 
when appropriate prophylactic procedures are prac-
ticed by charge physicians in settings where the use of 
a COX-2 selective inhibitor is not an option.  Our 
study showed that the pooled incidence rate for bleed-
ing is as low as 2.65 and 1.29 per 1,000 patient years 
for low-dose aspirin and non-aspirin NSAID users,  
respectively.
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